| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2148 | Fm-476 | Negative control for FM-381 |
|
| DCC2149 | Fm-743 | Negative control for Skepinone-L |
|
| DCC2150 | Fmf-01-086-2 | Novel highly selective inhibitor of Aurora kinases A, B and C, with potent cellular activity and minimal off-target activity (PLK4) |
|
| DCC2151 | Fmf-02-063-1 | Novel potent and selective Dual inhibitor of PI3K-δ and PI3K-γ |
|
| DCC2152 | Fmf-04-159-r | Novel potent dual CDK14 and CDK16 inhibitor |
|
| DCC2153 | Fmp-401319-3 | Novel concentration-dependent inhibitor of CRF1R-pPL cotranslational translocation at the level of the Sec61 complex |
|
| DCC2154 | Fnd-4b | Novel AMPK activator, inhibiting growth and induces apoptosis in colon cancer and increasing apoptosis in triple negative and estrogen-receptor positive breast cancers |
|
| DCC2155 | Fndr-20081 | First in class anti-tubercular agent against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb) |
|
| DCC2156 | Fnir-tag-co2h | Novel fluorescent near-infrared (NIR) linker for building brighter labeled biomolecules, exhibiting no evidence of H-aggregation even at high labeling density when appended to monoclonal antibodies or virus-like particles |
|
| DCC2157 | Fol7185 | Inhibitor of IspD and IspE enzymes isolated from bacteria |
|
| DCC2158 | Folate-arv-771 | Novel BRD PROTAC, being capable of degrading BRDs in a folate receptor-dependent manner in cancer cells |
|
| DCC2159 | Folate-ms99 | Novel ALK PROTAC, being capable of degrading ALK in a folate receptor-dependent manner in cancer cells |
|
| DCC2160 | Fomocaine | Local anaesthetic agent, blocking voltage-gated Na(+) currents in neurons |
|
| DCC2161 | Formyl Lenalidomide | Impurity of Lenalidomide |
|
| DCC2162 | Fosmidomycin | Natural antibiotic, acting as an inhibitor of DOXP reductoisomerase |
|
| DCC2163 | Fotagliptin | Novel dipeptidyl peptidase IV (DPP4) inhibitor |
|
| DCC2164 | Fotagliptin Benzoate | Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor |
|
| DCC2165 | Fotocaine | Novel Photochromic Ion Channel Blocker |
|
| DCC2166 | Fotyr-amp | Novel NO-donating antimicrobial peptide, exhibiting Staphylococcus aureus and Escherichia coli biofilm dispersion and eradication, and potent antibacterial activities in vitro |
|
| DCC2167 | Fpr-agonist-17b | Novel agonist of the formyl peptide receptor (FPR), protecting against myocardial ischaemia-reperfusion injury in mice |
|
| DCC2168 | Fr-139317 | Selective ET(A) receptor antagonist |
|
| DCC2169 | Fr171456 | Natural specific inhibitor of mammalian NSDHL and yeast Erg26p, inhibiting an artificial Hepatitis C viral replicon, and showung broad antifungal activity |
|
| DCC2170 | Fr181877 | Nonprostanoid PGI2 agonist |
|
| DCC2171 | Fr-190809 | Potent and nonadrenotoxic ACAT inhibitor |
|
| DCC2172 | Fr-190997 | Novel Nonpeptide Bradykinin B2-Receptor Partial Agonist |
|
| DCC2173 | Fr194921 | Potent, selective, and orally active antagonist for central adenosine A1 receptors |
|
| DCC2174 | Frf-01-116 | Novel Potent and Selective Covalent Inhibitor of KRAS G12C |
|
| DCC2175 | Fropofol | Potent ligand for a protein site governed largely by van der Waals interactions, producing excitatory activity in tadpoles and mice; also antagonizing propofol-induced hypnosis |
|
| DCC2176 | Fs2921 | Novel N-Methyl-d-aspartate receptor (NMDAR) positive allosteric modulator (PAM) with potential antidepressant effects |
|
| DCC2177 | Fs-694 | Novel highly potent and selective inhibitor (type 1.5 binding mode) of MAPK14 [IC50 = 0.2 nM (ELISA, cell free); KD = 1.5 nM (DiscoverX)] |
|
